Compare Medpace Holdings Inc (MEDP) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Victoria's Secret & Co — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Victoria's Secret & Co trades at $82.87 (market cap $6.91B). The key difference: Medpace Holdings Inc is far larger — about 2.4× Victoria's Secret & Co's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Victoria's Secret & Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Victoria's Secret & Co for 34 Days on average.
| MEDP | VSXY | |
|---|---|---|
Market Cap | $16.82B | $6.91B |
Volume | 223,093 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $99.97 |
52-Week Low | $393.42 | $28.25 |
Typical Hold Time | 14 Days | 34 Days |
Enterprise Value | $16.44B | $9.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Victoria's Secret (VSXY) trades at $86.61, up 0.96% with a bullish technical signal and strong analyst support. The stock shows improving fundamentals with three consecutive earnings beats and projected 2026 revenue growth to $6.9B. Recent news highlights brand momentum through fashion show expansion and omnichannel retail strategy driving international growth.
The outlook appears positive with 60% analyst buy ratings and $86.80 consensus target, though rich valuation (P/E 19.33) and rising costs present risks. Key catalysts include sustained margin improvement and global expansion execution, while competition and demand volatility remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
